These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 25654990)

  • 41. Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer.
    Lyskjær I; Kronborg CS; Rasmussen MH; Sørensen BS; Demuth C; Rosenkilde M; Johansen AFB; Knudsen M; Vang S; Krag SRP; Spindler KG; Andersen CL
    Sci Rep; 2019 Aug; 9(1):11542. PubMed ID: 31395942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment monitoring of colorectal cancer by integrated analysis of plasma concentration and sequencing of circulating tumor DNA.
    Yeh YM; Lin PC; Lee CT; Chen SH; Lin BW; Lin SC; Chen PC; Chan RH; Shen MR
    Mol Cancer; 2020 Oct; 19(1):150. PubMed ID: 33106181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating tumor DNA sequencing for colorectal cancers: A comparative analysis of colon cancer and rectal cancer data.
    Huang K; Qu H; Zhang X; Huang T; Sun X; He W; Li M; Lin L; Xu M; Chen S; Xia L
    Cancer Biomark; 2019; 26(3):313-322. PubMed ID: 31561327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer.
    Zou D; Day R; Cocadiz JA; Parackal S; Mitchell W; Black MA; Lawrence B; Fitzgerald S; Print C; Jackson C; Guilford P
    Carcinogenesis; 2020 Nov; 41(11):1507-1517. PubMed ID: 32955091
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
    Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
    J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer.
    Moati E; Blons H; Taly V; Garlan F; Wang-Renault SF; Pietrasz D; Didelot A; Garrigou S; Saint A; Pernot S; Taieb J; Laurent-Puig P; Zaanan A
    Int J Cancer; 2020 Aug; 147(4):1185-1189. PubMed ID: 31472013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
    Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
    Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring the HER2 copy number status in circulating tumor DNA by droplet digital PCR in patients with gastric cancer.
    Shoda K; Ichikawa D; Fujita Y; Masuda K; Hiramoto H; Hamada J; Arita T; Konishi H; Komatsu S; Shiozaki A; Kakihara N; Okamoto K; Taniguchi H; Imoto I; Otsuji E
    Gastric Cancer; 2017 Jan; 20(1):126-135. PubMed ID: 26874951
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
    Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
    Cells; 2019 May; 8(6):. PubMed ID: 31142037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Moon SM; Kim JH; Kim SK; Kim S; Kwon HJ; Bae JS; Lee S; Lee HS; Choi MY; Jeon BH; Jeong BH; Lee K; Kim HK; Kim J; Um SW
    Anticancer Res; 2020 Jun; 40(6):3435-3444. PubMed ID: 32487642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting Radiotherapy Responses and Treatment Outcomes Through Analysis of Circulating Tumor DNA.
    Chaudhuri AA; Binkley MS; Osmundson EC; Alizadeh AA; Diehn M
    Semin Radiat Oncol; 2015 Oct; 25(4):305-12. PubMed ID: 26384278
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparing single-target and multitarget approaches for postoperative circulating tumour DNA detection in stage II-III colorectal cancer patients.
    Henriksen TV; Reinert T; Rasmussen MH; Demuth C; Løve US; Madsen AH; Gotschalck KA; Iversen LH; Andersen CL
    Mol Oncol; 2022 Oct; 16(20):3654-3665. PubMed ID: 35895438
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted Sequencing of Circulating Tumor DNA to Monitor Genetic Variants and Therapeutic Response in Metastatic Colorectal Cancer.
    Hsu HC; Lapke N; Wang CW; Lin PY; You JF; Yeh CY; Tsai WS; Hung HY; Chiang SF; Chen HC; Chen SJ; Hsu A; Yang TS
    Mol Cancer Ther; 2018 Oct; 17(10):2238-2247. PubMed ID: 29997152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis.
    Bhangu JS; Beer A; Mittlböck M; Tamandl D; Pulverer W; Schönthaler S; Taghizadeh H; Stremitzer S; Kaczirek K; Gruenberger T; Gnant M; Bergmann M; Mannhalter C; Weinhäusel A; Oehler R; Bachleitner-Hofmann T
    Ann Surg; 2018 Nov; 268(5):894-902. PubMed ID: 30080722
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers.
    Veyer D; Wack M; Mandavit M; Garrigou S; Hans S; Bonfils P; Tartour E; Bélec L; Wang-Renault SF; Laurent-Puig P; Mirghani H; Rance B; Taly V; Badoual C; Péré H
    Int J Cancer; 2020 Aug; 147(4):1222-1227. PubMed ID: 31756275
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Free circulating DNA as possible tumour marker in colorectal cancer.
    Boni L; Cassinotti E; Canziani M; Dionigi G; Rovera F; Dionigi R
    Surg Oncol; 2007 Dec; 16 Suppl 1():S29-31. PubMed ID: 18024018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.